Factory Supply Best Olaparib Powder Price CAS 763113-22-0 99% Olaparib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• Purity: >99%
• CAS: 763113-22-0
• Model NO.: Olaparib
• Mf: C24h23fn4o3
• MW: 434.469
• Color: White
• Grade: Pharma Grade
• Storage: Cool Dry Place
• Shelf Life: 24month
• Transport Package: 1kg/Bag, 25kg/Drum
• Specification: Olaparib
• Trademark: HNB
• Origin: China
• Production Capacity: 1000kg/Month

Product Description

Product name	Olaparib
CAS NO.	763113-22-0
Synonyms	Olaparib
Category	Pharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals.
Purity	99% Olaparib
Appearance	Olaparib powder
Shelf life	2 years
Usage	Olaparib is an anticancer drug.
Storage	Olaparib should be stored in a well-closed container at low temperature, keep away from moisture, heat and light.
Note	Olaparib for R&D use only.

Olaparib is a new type of poly ADP ribose polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. PARP mediated a DNA repair mechanism, plays an important role in DNA damage repair and apoptosis, so Ola Pani specific effect on target cell DNA damage repair mechanism, by attacking the carrying BRCA1 and BRCA2 mutation critical vulnerabilities in cancer cells play a role, can be used for breast cancer susceptibility gene (BRCA) mutation and for the maintenance treatment of platinum sensitive recurrent severe ovarian cancer patients.

Indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
* Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
* Indicated for the treatment of patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, who have been previously treated with chemotherapy.